Gorlin Syndrome Epidemiology Forecast 2025-2034

Gorlin syndrome is a rare genetic disorder affecting 1 in 40,000-60,000 individuals globally, with equal gender distribution and only 5% of cases reported in African American and Asian populations. The Gorlin syndrome epidemiology forecast by Expert Market Research indicates the prevalence is almost equal in males as well as females.

Gorlin Syndrome Epidemiology Forecast Report Coverage

Expert Market Research's “Gorlin Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Gorlin syndrome. It projects the future incidence and prevalence rates of Gorlin syndrome cases across various populations. The study covers age, gender, and type as major determinants of the Gorlin syndrome population. The report highlights patterns in the prevalence of Gorlin syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Gorlin syndrome epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Gorlin Syndrome Understanding: Disease Overview

Gorlin syndrome, or nevoid basal cell carcinoma syndrome (NBCCS), is a rare autosomal dominant genetic disorder caused primarily by mutations in the PTCH1 gene, leading to dysregulation of the Hedgehog signaling pathway. It is characterized by multiple basal cell carcinomas, jaw keratocysts, skeletal abnormalities, and an increased risk of medulloblastoma. The condition exhibits variable expressivity, with symptoms appearing in childhood or adolescence. Early diagnosis is essential for surveillance and management of malignancy risks, given the syndrome’s lifelong predisposition to tumor development and tissue abnormalities.

Gorlin Syndrome Epidemiology Perspective

The Gorlin syndrome epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Gorlin syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Gorlin syndrome and their trends. The Gorlin syndrome detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Gorlin syndrome is a rare genetic disorder with a global prevalence estimated at 1 in 40,000-60,000 individuals.
• The condition affects both males and females nearly equally, with a male-to-female ratio of 1:1.3.
• While all races can be affected, African American and Asian populations account for only 5% of cases, often diagnosed incidentally with extracutaneous findings, such as odontogenic keratocysts, rather than basal cell carcinomas.

Country-wise Gorlin Syndrome Epidemiology Segment

The Gorlin syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, Gorlin syndrome a prevalence of approximately 1 in 31,000 individuals. It affects both males and females nearly equally and occurs across all ethnicities. The condition is more prevalent in Caucasians and African American and Asian populations represent a smaller proportion of cases. The syndrome is characterized by multiple basal cell carcinomas, jaw cysts, and other developmental anomalies. Early diagnosis and regular monitoring are essential to manage symptoms, prevent complications, and improve long-term outcomes for affected individuals.

Gorlin Syndrome: Treatment Overview

Treatment for Gorlin syndrome is multidisciplinary, focusing on tumor prevention, early detection, and management of associated anomalies. Surgical excision or laser ablation is used for basal cell carcinomas, while systemic therapies like Hedgehog pathway inhibitors (e.g., vismodegib, sonidegib) are effective in reducing tumor burden. Regular dermatologic, dental, and neurological evaluations are essential for early identification of complications. Supportive care includes genetic counseling for affected families and lifestyle modifications to minimize UV exposure, reducing the recurrence and progression of cutaneous and skeletal manifestations.

Key Questions Answered

• What are the key findings of Gorlin syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with Gorlin syndrome across the 8 major markets during the forecast period?
• What was the country-wise Gorlin syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of Gorlin syndrome during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Gorlin syndrome during the forecast period of 2025-2034?
• What are the currently available treatments for Gorlin syndrome?
• What are the disease risks, signs, symptoms, and unmet needs of Gorlin syndrome?

Scope of the Gorlin Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Gorlin syndrome based on several factors.
• Gorlin Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Gorlin syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.